Amolyt Pharma
Manufacturing · France · 11-50 Employees
View Company Info for Free
Overview
Headquarters
15 Chemin Du Saquin Espace Européen Bldg...Phone Number
+33 472189428Website
www.amolytpharma.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About Amolyt Pharma
Founded in 2014, Amolyt Pharma is a clinical-stage biotechnology company, that specializes in advancing peptides for the treatment of rare endocrine and metabolic disorders. Amolyt Pharma is located in FranceExplore more
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Amolyt Pharma your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Amolyt Pharma launches new products
Congratulate Masked Content for being promoted to Masked Content at Amolyt Pharma
Check out if Amolyt Pharma is spiking on competitors!
Click to see if Amolyt Pharma had a recent Job posting/layoffs
Check if Amolyt Pharma has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Amolyt Pharma recently announced quarterly report
Amolyt Pharma, which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Amolyt Pharma has new funding data
Recommended Actions
Reach out to Masked Content who joined Amolyt Pharma as Masked Content
Find more new buyers
Company Profile Activity
Activity Insights
Amolyt Pharma is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Amolyt Pharma is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Amolyt Pharma.
Amolyt Pharma financials insights
Gather financial insights about Amolyt Pharma, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Private Equity
$6.6M
2015
Unspecified
$1.9M
2016
Private Equity
$17.1M
2019
Series A
$72.9M
2021
Series B
$80M
2023
Series C
$138M
Amolyt Pharma Tech Stack
A closer look at the technologies used by Amolyt Pharma
See more technologies
Most Recent Scoops
Mergers & Acquisitions (M&A)
Mergers & Acquisitions
Funding
Event
will be attending the 2022 BIO International Convention conference as an exhibitor. The event will occur from June 13 to June 16, 2022.
Funding
Amolyt Pharma News & Media
AstraZeneca Closes Acquisition of Amolyt Pharma
LYON, France and CAMBRIDGE, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global, clinical-stage biopharmaceutical company specializing in developing therapeutic peptides for rare endocrine and related diseases, today announced that its previously announced acquisition by the global pharmaceutical company, AstraZeneca, has closed.Amolyt Pharma Announces Abstracts Accepted for Presentation at the GRS Congress, ECE and ENDO
LYON, France and CAMBRIDGE, Mass., May 07, 2024 (GLOBE NEWSWIRE) -- Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced that the company has had multiple abstracts accepted for presentation at the 10th International Congress of the Growth Hormone Research Society (GRS), which is being held May 10-11 in Stockholm, Sweden, the 26th European Congress of Endocrinology (ECE), which is being held May 11-14 in StockholmAmolyt Pharma Granted FDA Fast Track Designation for Eneboparatide for the Treatment of Hypoparathyroidism
Designation reflects the seriousness of the disease and the potential for eneboparatide to address the urgent need for new treatment options that address key treatment goals in hypoparathyroidism Designation reflects the seriousness of the disease and the potential for eneboparatide to address the urgent need for new treatment options that address key treatment goals in hypoparathyroidism
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Amolyt Pharma
Sign Up For FreeTo access detailed company insights
Founded in 2014, Amolyt Pharma is a clinical-stage biotechnology company, that specializes in advancing peptides for the treatment of rare endocrine and metabolic disorders. Amolyt Pharma is located in France... Read More
